Sugi Predict

Sugi Predict / Compounds / SCHEMBL6284695

SCHEMBL6284695

SCHEMBL6284695

COc1ccc(C(OC[C@H]2O[C@@H](n3ccc(=O)[nH]c3=O)[C@H](OC)[C@@H]2O)(c2ccccc2)c2ccc(OC)cc2)cc1

nearest known ligand 0.53

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
▸ TYMP P19971 1/20 0.53
▸ P2RY14 Q15391 5/20 0.51
▸ P2RY2 P41231 10/20 0.46
▸ P2RY6 Q15077 8/20 0.46
▸ P2RY4 P51582 4/20 0.45
▸ SLC28A1 O00337 1/20 0.44
▸ SLC28A2 O43868 1/20 0.44
▸ SLC29A1 Q99808 1/20 0.44
▸ SLC28A3 Q9HAS3 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6284697 1.00 TYMP (0.53) TYMPP2RY14P2RY2P2RY6P2RY4
SCHEMBL3721728 1.00 TYMP (0.53) TYMPP2RY14P2RY2P2RY6P2RY4
SCHEMBL19709158 1.00 TYMP (0.53) TYMPP2RY14P2RY2P2RY6P2RY4
SCHEMBL19709160 1.00 TYMP (0.53) TYMPP2RY14P2RY2P2RY6P2RY4
SCHEMBL19549038 1.00 TYMP (0.53) TYMPP2RY14P2RY2P2RY6P2RY4
SCHEMBL20828930 1.00 TYMP (0.53) TYMPP2RY14P2RY2P2RY6P2RY4
SCHEMBL13837117 0.93 TYMP (0.52) TYMPP2RY14P2RY2P2RY6P2RY4
SCHEMBL20603110 0.93 TYMP (0.52) TYMPP2RY14P2RY2P2RY6P2RY4
SCHEMBL21905171 0.93 TYMP (0.52) TYMPP2RY14P2RY2P2RY6P2RY4
SCHEMBL10592428 0.93 TYMP (0.53) TYMPP2RY14P2RY2P2RY6P2RY4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4745238-A1 OLIGONUCLEOTIDE TARGETING ANGIOTENSINOGEN AND USE THEREOF Anlong Biopharmaceutical Co., Ltd. (CN) 2026-05-20 — — EP disclosed
EP-4741411-A2 OLIGONUCLEOTIDE PRODUCTION METHOD, AND NUCLEOSIDE, NUCLEOTIDE, OR OLIGONUCLEOTIDE AJINOMOTO CO., INC. (JP) 2026-05-13 — — EP disclosed
EP-3221330-B1 PHOSPHORAMIDITE SYNTHONES FOR THE SYNTHESIS OF SELF-NEUTRALIZING OLIGONUCLEOTIDE COMPOUNDS ZATA PHARMACEUTICALS INC (US) 2026-04-22 — — EP disclosed
EP-4720286-A2 SOD1-MODULATING COMPOSITIONS AND METHODS OF USE THEREOF Adarx Pharmaceuticals, Inc. (US) 2026-04-08 — — EP disclosed
US-12509484-B2 Method of producing nucleic acid compound, and nucleic acid compound FUJIFILM CORPORATION (JP) 2025-12-30 — — US disclosed
WO-2025264952-A2 NOVEL RNA THERAPEUTICS AND USES THEREOF ELI LILLY AND COMPANY (US) 2025-12-26 — — WO disclosed
US-12441756-B2 5′-cyclo-phosphonate modified nucleotides Arrowhead Pharmaceuticals, Inc. (US) 2025-10-14 — — US disclosed
US-20250312367-A1 OLIGONUCLEOTIDES HAVING A SYNTHETIC BACKBONE AND SYNTHESIS THEREOF ADARX PHARMACEUTICALS, INC. (US) 2025-10-09 — — US disclosed
WO-2025087442-A1 OLIGONUCLEOTIDE TARGETING LIPOPROTEIN A AND USE THEREOF 北京安龙生物医药有限公司 2025-05-01 — — WO disclosed
WO-2025077916-A1 TRANSTHYRETIN-TARGETING OLIGONUCLEOTIDE AND USE THEREOF 北京安龙生物医药有限公司 2025-04-17 — — WO disclosed
EP-1223173-A2 Novel 2'-O-alkyl nucleosides and phosphoramidites processes for the preparation and uses thereof ISIS PHARMACEUTICALS, INC. (US) 2002-07-17 — — EP disclosed
US-6242592-B1 Process for the preparation of 2′-O-alkyl-guanosine, cytidine, and uridine phosphoramidites ISIS PHARMACEUTICALS, INC. 2001-06-05 — — US disclosed
US-6133438-A Process for the preparation of 2'-O-alkyl purine phosphoramidites ISIS PHARMACEUTICALS, INC. (US) 2000-10-17 — — US disclosed
US-6090932-A Method of preparation of known and novel 2'-modified nucleosides by intramolecular nucleophilic displacement PROLIGO LLC (US) 2000-07-18 — — US disclosed
US-5914396-A 2'-O-modified nucleosides and phosphoramidites ISIS PHARMACEUTICALS, INC. (US) 1999-06-22 — — US disclosed
US-5856466-A Process for the preparation of 2'-O-alkyl purine phosphoramidites ISIS PHARMACEUTICALS, INC. (US) 1999-01-05 — — US disclosed
US-5646265-A Process for the preparation of 2'-O-alkyl purine phosphoramidites ISIS PHARMCEUTICALS, INC. (US) 1997-07-08 — — US disclosed
EP-0260032-B1 Compounds for the cleavage at a specific position of RNA, oligomers employed for the formation of said compounds, and starting materials for the synthesis of said oligomers AJINOMOTO KK (JP) 1994-01-26 — — EP disclosed
US-5013830-A Genetic engineering AJINOMOTO CO., INC. (JP) 1991-05-07 — — US disclosed
EP-0260032-A2 Compounds for the cleavage at a specific position of RNA, oligomers employed for the formation of said compounds, and starting materials for the synthesis of said oligomers AJINOMOTO CO., INC. (JP) 1988-03-16 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12441756-B2 5′-cyclo-phosphonate modified nucleotides ENPP1, DCTPP1, PNKP TYMP 29/4885P2RY14 2252/4885P2RY2 2427/4885
US-20250312367-A1 OLIGONUCLEOTIDES HAVING A SYNTHETIC BACKBONE AND SYNTHESIS THEREOF POLRMT, TARDBP, NSUN2 TYMP 77/4885P2RY14 2588/4885P2RY2 2480/4885
US-12509484-B2 Method of producing nucleic acid compound, and nucleic acid compound NSUN2, RNASEH1, XRN2 TYMP 586/4885P2RY14 4354/4885P2RY2 3442/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.